<?xml version="1.0" encoding="UTF-8"?>
<p id="p0575">It is also essential that countries and regions plan for real and coincidental AESIs and AEFIs with a scientifically rigorous and publicly credible process to separate real adverse reactions from coincidental background rates of disease. Safety signals require careful evaluation often involving chart review of potential cases, which can be both time and labor intensive. As recommended by the WHO Global Vaccine Safety Blueprint (GVSB 2.0), “Countries or regions establish either a national expert committee for AEFIs or regional advisory committees or equivalent objective panels with spelled out terms of reference 
 <xref rid="b0050" ref-type="bibr">[13]</xref>.” Public credibility can be optimized by ensuring that these committees are “independent of conflicts of interest with the ministries of health, industry and the immunization program”. Vaccine safety communication plans, with clear national and subnational vaccine safety communication roles and responsibilities, should be developed to provide timely, evidence-based messaging to describe what is known, what is not known, and what is being done to fill these gaps.
</p>
